Key result
Newer-generation rotavirus vaccines may help scale up vaccination in poorer countries.
Locally produced and newer-generation rotavirus vaccines could improve vaccine coverage in low- and middle-income countries.
Rotavirus vaccine rollout lags in Asian LMICs; leaves open targeted implementation research to close coverage gaps.
There are two internationally available WHO-prequalified oral rotavirus vaccines (Rotarix and RotaTeq), two rotavirus vaccines licensed in India (Rotavac and Rotasiil), one in China (Lanzhou lamb rotavirus vaccine) and one in Vietnam (Rotavin-M1), and several candidates in development. Rotavirus vaccination has been rolled out in Latin American countries and is beginning to be deployed in sub-Saharan African countries but middle- and low-income Asian countries have lagged behind in rotavirus vaccine introduction. We provide a mini-review of the leading newer-generation rotavirus vaccines and compare them with Rotarix and RotaTeq. We discuss how the development and future availability of newer-generation rotavirus vaccines that address the programmatic needs of poorer countries may help scale-up rotavirus vaccination where it is needed.
No takes yet. Share an insight, caveat, or question.
Deen et al. (2017) conducted a review in Rotavirus infection. Newer-generation rotavirus vaccines vs. Rotarix and RotaTeq was evaluated. Newer-generation rotavirus vaccines that address the programmatic needs of poorer countries may help scale-up rotavirus vaccination where it is needed.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: